EMCURE PHARMACEUTICALS
AMFI reshuffle: Jio Platforms and NSE may get largecap status, Vedanta may become midcap in H1 CY27
Nuvama expects Jio Platforms and NSE to enter AMFI's largecap category in its H1 CY27 reshuffle, while Vedanta may move to midcap status. The proposed changes also include upgrades and downgrades across midcap and smallcap stocks, with revised market-cap thresholds estimated at Rs 1.12 lakh crore and Rs 36,700 crore.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 crore
Emcure Pharmaceuticals Ltd has posted a remarkable consolidated net profit of Rs 325.06 crore for the September quarter, reflecting substantial growth. Revenue surged from Rs 2,269.82 crore to Rs 2,820.47 crore during this period, with international operations increasing by 34 per cent. Additionally, domestic revenue witnessed an 11.1 per cent rise, as company leaders expressed confidence in sustaining this positive trend through the latter half of FY27.
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Emcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore. Revenue grew 24.3%, while EBITDA rose 30.9%, supported by strong international business growth.
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.
- Go To Page 1

AMFI reshuffle: NSE may get largecap status, SBI Fund Management may become midcap in H1 CY27
Nuvama expects NSE to enter the largecap category and SBI Funds Management to become a midcap in AMFI’s H1 CY27 reshuffle. Bosch, Siemens Energy India and others may be upgraded, while several largecaps could move down. The revised classification will take effect from February 1, 2027, after H2 CY26 market-cap rankings.

Ahead of Market: 10 things that will decide stock market action on Monday
Indian equities extended their recovery, with Nifty gaining 0.33% as moderation in crude and global yields supported sentiment. Sensex slipped 0.03%, while broader markets outperformed. Here are 10 key factors that could influence Friday’s market action.

Emcure Pharma net profit up 36% at Rs 292 crore
Emcure Pharmaceuticals reported a 23% revenue increase in the first quarter. Ebitda grew 25.8% with improved margins, reflecting productivity gains. Net profit saw a significant 36.2% rise during the period. The company began its five-year plan on a strong footing for FY27. Emcure also completed the acquisition of a minority stake in Gennova Biopharmaceuticals.

PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Emcure Pharma shares in focus after GST Department conducts search at Mumbai offices
Emcure Pharmaceuticals' shares could see action following a Goods and Services Tax search at its Mumbai offices. The inspection concluded this week. The company recently reported a robust rise in revenue and profit after tax. Domestic and international businesses both showed strong performance.

Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth
Emcure Pharmaceuticals reported a strong first quarter with a 41% increase in net profit, reaching Rs 215 crore, and a 16% rise in revenue to Rs 2,101 crore. Growth was fueled by robust domestic and international performance, particularly in the rest of the world and Canada.

Emcure, Sanofi sign distribution pact for oral anti-diabetic products in India
Emcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic products like Amaryl and Cetapin. Sanofi India will continue to manufacture these brands. This collaboration aims to make these medicines more accessible across India. The partnership will benefit patients and healthcare professionals. There will be no staff transition from Sanofi India to Emcure.

Emcure Pharma to acquire remaining 20.42% stake in Zuventus Healthcare for Rs 724.9 cr
Emcure Pharmaceuticals will acquire the remaining 20.42% stake in Zuventus Healthcare Ltd from minority shareholders for ₹724.9 crore, a move approved by its board. This acquisition, expected to close in the September quarter of FY26, will make Zuventus a wholly-owned subsidiary. Emcure aims to fully consolidate Zuventus financially, driving long-term value creation and unlocking synergies within its domestic business.

Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir
Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.

Emcure Pharmaceuticals IPO booked nearly 68 times so far on Day 3. Check GMP and other details
Emcure Pharmaceuticals IPO sees strong demand with oversubscription. Anchor investors include top names. Company engaged in global pharmaceutical products. Revenue growth and plans for debt payment outlined. Book-running lead managers identified.

Emcure Pharmaceuticals IPO fully subscribed on Day 1. Check GMP and other details
Emcure Pharmaceuticals' IPO attracts high demand from investors, with a price range of Rs 960-1008 per share. Analysts foresee business improvements and revenue growth potential in the global pharmaceutical market, supporting the company's expansion strategies.

Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other details
Emcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on July 5. The categories reserved for NII and retail investors were subscribed the most at 13 times and 3.43 times, respectively.

Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.

Emcure Pharma announces price band for Rs 1,952-crore IPO at Rs 960-1,008/share. Check GMP, other details
Emcure Pharmaceuticals has announced its initial public offering (IPO) with a price band of Rs 960 to Rs 1,008 per equity share. The subscription for the IPO will open on Wednesday, July 3, and close on Friday, July 5. The floor price and cap price of the issue are set at 96 times and 100.80 times the face value of the equity shares, respectively.

Emcure Pharmaceuticals receives SEBI nod for its IPO launch
Emcure Pharmaceuticals received SEBI nod for IPO launch after filing DRHP in December 2023. The IPO includes equity shares and an Offer of Sale by promoters. Proceeds will be used for debt payment. Emcure Pharmaceuticals is renowned for its global marketing of pharmaceutical products.

Emcure Pharma to launch IPO in 3 months: Namita Thapar of Shark Tank fame
Shark Tank fame and Executive Director of Emcure Pharmaceuticals, Namita Thapar said at the ET NOW Global Business Summit 2024 on February 10 that the company plans to go public within three months.

Emcure Pharma gets relief in $950-million lawsuit
The US district judge James Robart upheld the Indian drug maker's argument that the court lacked jurisdiction over the company and dismissed the case without prejudice, which means it can be refiled.

Emcure Pharmaceuticals acquires Canadian company and its marketing arm Marcan
Marcan Pharma has over 60 approved products that are mainly available via McKesson and Kohl & Frisch, among other wholesalers, it claimed.

Emcure Pharmaceuticals withdraws proposed IPO
The Pune-based pharma company had filed draft offer documents with the Securities and Exchange Board of India (Sebi) for the proposed IPO in June last year.

Blackstone to sell its stake in Emcure Pharma to Bain Capital
Private equity major Blackstone is selling its stake in Pune-based Emcure Pharmaceuticals to Bain Capital.

Emcure Pharmaceuticals files DRHP for IPO
Emcure Pharmaceuticals today said it has filed a DRHP with the SEBI for launching an initial public offer to raise an estimated Rs 300 crore.
Load More